ad image

Articles
Expert Interviews
Roundtable
Press Releases
Videos

Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing

Company Info

Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us
Nice Insight
That's Nice

Reach Our Team

Contact Us
Advertise

My Account

Login/Sign up

Site

Privacy Policy
Terms And Conditions

© 2024 PHARMA’S ALMANAC. All rights reserved.

GBI

Headquarters

1850 N.W. 69th Avenue,

Plantation FL 33313

USA

Visit the Website

GBI

CDMO

Overview

GBI is a full-service CDMO offering a Single-Source Solution™ to flexibly accommodate biologics manufacturing projects at all stages including process tech transfer, scale-up, and cGMP manufacturing of the bulk drug substance and vialed drug product for preclinical and early phase through late-phase clinical trials and commercial usage.

Visit GBI’s new website and reach out to discuss your CMC outsourcing strategy at www.gbibio.com.

5 Contributors1 / 1

1 / 1

8 Contributions1 / 1

1 / 1

Natalia Bourguignon, Ph.D.

Natalia Bourguignon, Ph.D.

Manager, MSAT-USP

Joandiet Castaneda

Senior Manager, MSAT

Hyung-il Lee, Ph.D.

Senior Scientist, Bioconjugation

Andrew Majdoch, M.Sc.

Andrew Majdoch, M.Sc.

Vice President of Technical Operations

Muctarr Sesay, Ph.D.

Muctarr Sesay, Ph.D.

The Improvements of the Production and Stability of a mAb-Chelator Conjugate by Modified Transchelation Conditions

CDMO

The Improvements of the Production and Stability of a mAb-Chelator Conjugate by Modified Transchelation Conditions

Hyung-il Lee, Ph.D.

GBI

PAO-11-24-CL-09Nov 22, 2024

DoE for Clone Selection and Process Development to Meet Biosimilar Critical Qualities Attributes and High Productivity

Biosimilars

DoE for Clone Selection and Process Development to Meet Biosimilar Critical Qualities Attributes and High Productivity

Natalia Bourguignon, Ph.D.; Joandiet Castaneda; Andrew Majdoch, M.Sc.

GBI

PAO-09-24-CL-08Sep 12, 2024

Expediting Radioimmune Conjugate Pharmaceuticals for First-In-Human Phase 0 Proof-of-Concept Human Studies from Stable Pool

Radioconjugate development

Expediting Radioimmune Conjugate Pharmaceuticals for First-In-Human Phase 0 Proof-of-Concept Human Studies from Stable Pool

Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.

GBI

PAO-03-24-CL-07Mar 15, 2024

Reach the Patient Quicker with GBI’s Manufacturing Solutions

Clinical and Commercial Manufacturing

Reach the Patient Quicker with GBI’s Manufacturing Solutions

Muctarr Sesay, Ph.D.

GBI

PAO-08-23-CL-02Aug 08, 2023

GBI

CDMO

Goodwin Biotechnology Inc. is Now GBI, as Part of their Rebranding Initiative on Their 30-Year Anniversary!

GBI

PR-M12-22-02-179Dec 09, 2022

Vaccines Present a Novel Strategy for Opioid Overdose Prevention

Opioid Conjugate Vaccines

Vaccines Present a Novel Strategy for Opioid Overdose Prevention

Muctarr Sesay, Ph.D.

GBI

PAO-10-022-CL-07Oct 31, 2022

Leveraging Experience to Reduce Timelines for IND-Enabling Activities

Speed to Clinic

Leveraging Experience to Reduce Timelines for IND-Enabling Activities

Muctarr Sesay, Ph.D.; Andrew Majdoch, M.Sc.

GBI

PAO-09-022-CL-04Sep 19, 2022

Theranostic Manufacturing Solutions

Theranostics

Theranostic Manufacturing Solutions

Muctarr Sesay, Ph.D.

GBI

PAO-08-022-CL-07Aug 29, 2022